Trastuzumab biosimilar - United BioPharma

Drug Profile

Trastuzumab biosimilar - United BioPharma

Alternative Names: UB 921

Latest Information Update: 20 Jan 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator United BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 02 Jan 2017 United BioPharma, in collaboration with Tri-Service General Hospital, plans a phase I trial in Healthy volunteers in Taiwan in June 2017 (NCT03013881)
  • 02 Jan 2017 Preclinical trials in Breast cancer in Taiwan (Parenteral) before January 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top